Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Eric Gutflais

Neurology San Diego, CA Medical Doctor

NPI 1700231339 CMS profile 8801638

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$5,676

25 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Gutflais of San Diego, CA is reported in the CMS Open Payments database as having received $5,676 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $549 20
2021 General $114 3
2020 General $5,012 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Gutflais
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Eric Gutflais were reported at $549. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Eric Gutflais Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $5,012 $367 $82–$2,309 $114
2021 $114 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $549 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic USA, Inc. $5,000 1 payment
  2. AbbVie, Inc. $410 13 payments
  3. Merz Pharmaceuticals, LLC $101 2 payments
  4. Pfizer Inc. $51 3 payments
  5. Teva Pharmaceuticals USA, Inc. $39 2 payments
  6. ACADIA Pharmaceuticals Inc $34 2 payments
  7. Janssen Biotech, Inc. $27 1 payment
  8. Merz North America, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $5,000 1 payment
  2. Food and Beverage $596 23 payments
  3. Education $80 1 payment
Products named General payments · program years 2020–2025
  1. ACTIVA $5,000 1 payment
  2. BOTOX Botox Therapeutic $254 11 payments
  3. BOTOX Neuroscience $156 2 payments
  4. NURTEC ODT $51 3 payments
  5. ZAVZPRET $51 3 payments
  6. Austedo XR $39 2 payments
  7. NUPLAZID $34 2 payments
  8. Xeomin musculoskeletal $21 1 payment
  9. Xeomin musculoskeletal $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

537

Median for Neurology: 833

Drug cost

$88,789

Median for Neurology: $202,670

Branded share of claims

24.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 32 $36,217
Emgality Pen Galcanezumab-Gnlm Brand 24 $29,814
Lacosamide Generic 29 $10,544
Gabapentin Generic 124 $3,974
Carbidopa-Levodopa Carbidopa/Levodopa Brand 57 $2,474
Levetiracetam Generic 37 $1,121
Pregabalin Generic 48 $977
Propranolol Hcl Er Propranolol Hcl Brand 18 $882
Duloxetine Hcl Generic 27 $617
Lamotrigine Generic 20 $486

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$119,811

Of which drugs: $64,484

Medicare patients

239

Average age 70

Services billed

14,394

148 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 63%
Depression 42%
Osteoporosis 32%
Chronic kidney disease 25%
Diabetes 24%
Ischemic heart disease 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 25 10,400 $51,268

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record